CAR T cells produced in vivo to treat cardiac injury-Reference-Cited by-同舟云学术

CAR T cells produced in vivo to treat cardiac injury

Published:2022-01-07 Issue:6576 Volume:375 Page:91-96
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Rurik Joel G.¹²³^ORCID,Tombácz István⁴^ORCID,Yadegari Amir⁴^ORCID,Méndez Fernández Pedro O.¹²³^ORCID,Shewale Swapnil V.²,Li Li¹²^ORCID,Kimura Toru⁴^ORCID,Soliman Ousamah Younoss⁴^ORCID,Papp Tyler E.⁴^ORCID,Tam Ying K.⁵,Mui Barbara L.⁵,Albelda Steven M.⁴⁶^ORCID,Puré Ellen⁷^ORCID,June Carl H.⁶^ORCID,Aghajanian Haig¹²³^ORCID,Weissman Drew⁴^ORCID,Parhiz Hamideh⁴^ORCID,Epstein Jonathan A.¹²³⁴^ORCID

Affiliation:

1. Department of Cell and Developmental Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

2. Penn Cardiovascular Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

3. Institute for Regenerative Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

4. Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

5. Acuitas Therapeutics, Vancouver, British Columbia V6T 1Z3, Canada.

6. Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

7. Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Abstract

Making CAR T cells in vivo Cardiac fibrosis is the stiffening and scarring of heart tissue and can be fatal. Rurik et al . designed an immunotherapy strategy to generate transient chimeric antigen receptor (CAR) T cells that can recognize the fibrotic cells in the heart (see the Perspective by Gao and Chen). By injecting CD5-targeted lipid nanoparticles containing the messenger RNA (mRNA) instructions needed to reprogram T lymphocytes, the researchers were able to generate therapeutic CAR T cells entirely inside the body. Analysis of a mouse model of heart disease revealed that the approach was successful in reducing fibrosis and restoring cardiac function. The ability to produce CAR T cells in vivo using modified mRNA may have a number of therapeutic applications. —PNK

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference36 articles.

1. Fibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis

2. IL-11 is a crucial determinant of cardiovascular fibrosis

3. Resident fibroblast lineages mediate pressure overload–induced cardiac fibrosis

4. Type V Collagen in Scar Tissue Regulates the Size of Scar after Heart Injury

5. Immune Cells and Immunotherapy for Cardiac Injury and Repair

Cited by 396 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advancements in nanotechnology based drug delivery for the management of cardiovascular disease;Current Problems in Cardiology;2024-04

2. Manufacture of CD22 CAR T cells following positive versus negative selection results in distinct cytokine secretion profiles and γδ T cell output;Molecular Therapy - Methods & Clinical Development;2024-03

3. Protein-based nanoparticles for therapeutic nucleic acid delivery;Biomaterials;2024-03

4. Precision treatment of viral pneumonia through macrophage-targeted lipid nanoparticle delivery;Proceedings of the National Academy of Sciences;2024-02-05

5. BioCanRx Summit for Cancer Immunotherapy 2022 Proceedings;Biochemistry and Cell Biology;2024-02-01